AR102890A1 - Polipéptidos que comprenden una secuencia de aminoácidos g3p de bacteriófago sin señal de glucosilación - Google Patents
Polipéptidos que comprenden una secuencia de aminoácidos g3p de bacteriófago sin señal de glucosilaciónInfo
- Publication number
- AR102890A1 AR102890A1 ARP150103956A ARP150103956A AR102890A1 AR 102890 A1 AR102890 A1 AR 102890A1 AR P150103956 A ARP150103956 A AR P150103956A AR P150103956 A ARP150103956 A AR P150103956A AR 102890 A1 AR102890 A1 AR 102890A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptides
- amino acids
- amyloids
- modified
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se referencia a polipéptidos que comprenden una parte de proteína 3 del gen de bacteriófago filamentoso (g3p) suficiente para unirse y/o separar amiloides, p. ej., la parte N1-N2 de g3p y mutantes y fragmentos de esta, en la que la secuencia de aminoácidos de g3p se modificó mediante eliminación, inserción o sustitución de aminoácidos para retirar una señal de glucosilación putativa. También hace referencia a los polipéptidos que también se modifican mediante otra sustitución de aminoácidos para ser sustancialmente menos inmunogénicos que la secuencia de aminoácidos de g3p de tipo salvaje correspondiente cuando se utilizan in vivo. Los polipéptidos mantienen su capacidad de unirse y/o separar amiloides. También al uso de estos polipéptidos modificados con g3p en el tratamiento y/o la prevención de enfermedades asociadas con el mal plegamiento o la agregación de amiloides.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087052P | 2014-12-03 | 2014-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102890A1 true AR102890A1 (es) | 2017-03-29 |
Family
ID=55273507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103956A AR102890A1 (es) | 2014-12-03 | 2015-12-03 | Polipéptidos que comprenden una secuencia de aminoácidos g3p de bacteriófago sin señal de glucosilación |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10722551B2 (es) |
| EP (1) | EP3227313B1 (es) |
| JP (2) | JP6730988B2 (es) |
| KR (1) | KR20170085132A (es) |
| CN (1) | CN107250154A (es) |
| AR (1) | AR102890A1 (es) |
| AU (1) | AU2015358504A1 (es) |
| BR (1) | BR112017011530A2 (es) |
| CA (1) | CA2969128A1 (es) |
| DK (1) | DK3227313T3 (es) |
| EA (1) | EA201791212A1 (es) |
| ES (1) | ES2910017T3 (es) |
| IL (1) | IL252426A0 (es) |
| MX (1) | MX2017007059A (es) |
| PH (1) | PH12017501004A1 (es) |
| PL (1) | PL3227313T3 (es) |
| PT (1) | PT3227313T (es) |
| SG (1) | SG11201704427YA (es) |
| TW (1) | TW201632542A (es) |
| WO (1) | WO2016090022A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012346056B2 (en) | 2011-11-29 | 2018-02-22 | Proclara Biosciences, Inc. | Use of P3 of bacteriophage as amyloid binding agents |
| SI2906235T1 (sl) | 2012-10-02 | 2017-12-29 | Proclara Biosciences, Inc. | Uporaba P3 bakteriofagnih fuzijskih proteinov kot amiloidnih vezavnih sredstev |
| EA030389B1 (ru) | 2013-05-28 | 2018-07-31 | Проклара Байосайенсиз, Инк. | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ИЗМЕНЕННУЮ АМИНОКИСЛОТНУЮ ПОСЛЕДОВАТЕЛЬНОСТЬ g3p БАКТЕРИОФАГА С ПОНИЖЕННОЙ ИММУНОГЕННОСТЬЮ |
| SG11201704427YA (en) | 2014-12-03 | 2017-06-29 | Proclara Biosciences Inc | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
| ES2960493T3 (es) * | 2018-06-15 | 2024-03-05 | Amyl Therapeutics | Motivo de interacción amiloide general (GAIM) |
| WO2024119183A1 (en) | 2022-12-02 | 2024-06-06 | Alzheon, Inc. | Methods for treating neurodegenerative disorders with tramiprosate |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| ATE236249T1 (de) | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1993024135A1 (en) | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
| EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
| ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| JP2004532620A (ja) | 2001-02-19 | 2004-10-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 免疫原性の低減された人工タンパク質 |
| PL362986A1 (en) | 2001-03-08 | 2004-11-15 | Merck Patent Gmbh | Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
| DE10238846A1 (de) | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
| PT1853285E (pt) | 2005-02-01 | 2011-06-06 | Univ Ramot | Método para tratamento de inflamação associada a depósitos de amilóide e inflamação cerebral envolvendo microglia activada |
| AU2007214399A1 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel-Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
| WO2007094003A2 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
| US20090105090A1 (en) | 2006-04-06 | 2009-04-23 | Fumiaki Uchiyama | Phage Display By Novel Filamentous Bacteriophage |
| US20090324554A1 (en) | 2006-07-21 | 2009-12-31 | Ramot At Tel Aviv University Ltd. | Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates |
| WO2008044032A2 (en) | 2006-10-11 | 2008-04-17 | Antitope Limited | T cell epitope databases |
| WO2009143470A1 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
| EP2358377A2 (en) | 2008-11-24 | 2011-08-24 | Ramot at Tel-Aviv University Ltd. | Method for treating parkinson's disease using filamentous bacteriophage |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| KR20140051840A (ko) | 2011-03-11 | 2014-05-02 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 신경변성 타우오패씨를 치료하는 방법 |
| AU2012346056B2 (en) | 2011-11-29 | 2018-02-22 | Proclara Biosciences, Inc. | Use of P3 of bacteriophage as amyloid binding agents |
| SI2906235T1 (sl) | 2012-10-02 | 2017-12-29 | Proclara Biosciences, Inc. | Uporaba P3 bakteriofagnih fuzijskih proteinov kot amiloidnih vezavnih sredstev |
| EA030389B1 (ru) | 2013-05-28 | 2018-07-31 | Проклара Байосайенсиз, Инк. | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ИЗМЕНЕННУЮ АМИНОКИСЛОТНУЮ ПОСЛЕДОВАТЕЛЬНОСТЬ g3p БАКТЕРИОФАГА С ПОНИЖЕННОЙ ИММУНОГЕННОСТЬЮ |
| SG11201704427YA (en) | 2014-12-03 | 2017-06-29 | Proclara Biosciences Inc | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
-
2015
- 2015-12-02 SG SG11201704427YA patent/SG11201704427YA/en unknown
- 2015-12-02 EA EA201791212A patent/EA201791212A1/ru unknown
- 2015-12-02 CN CN201580065696.9A patent/CN107250154A/zh active Pending
- 2015-12-02 PT PT158310110T patent/PT3227313T/pt unknown
- 2015-12-02 MX MX2017007059A patent/MX2017007059A/es unknown
- 2015-12-02 EP EP15831011.0A patent/EP3227313B1/en active Active
- 2015-12-02 KR KR1020177017763A patent/KR20170085132A/ko unknown
- 2015-12-02 JP JP2017529043A patent/JP6730988B2/ja active Active
- 2015-12-02 AU AU2015358504A patent/AU2015358504A1/en not_active Abandoned
- 2015-12-02 TW TW104140347A patent/TW201632542A/zh unknown
- 2015-12-02 PL PL15831011T patent/PL3227313T3/pl unknown
- 2015-12-02 WO PCT/US2015/063476 patent/WO2016090022A1/en active Application Filing
- 2015-12-02 BR BR112017011530A patent/BR112017011530A2/pt not_active Application Discontinuation
- 2015-12-02 DK DK15831011.0T patent/DK3227313T3/da active
- 2015-12-02 ES ES15831011T patent/ES2910017T3/es active Active
- 2015-12-02 US US15/532,820 patent/US10722551B2/en active Active
- 2015-12-02 CA CA2969128A patent/CA2969128A1/en not_active Abandoned
- 2015-12-03 AR ARP150103956A patent/AR102890A1/es unknown
-
2017
- 2017-05-22 IL IL252426A patent/IL252426A0/en unknown
- 2017-05-31 PH PH12017501004A patent/PH12017501004A1/en unknown
-
2020
- 2020-02-19 JP JP2020026300A patent/JP2020073610A/ja not_active Withdrawn
- 2020-06-18 US US16/905,128 patent/US11723951B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2969128A1 (en) | 2016-06-09 |
| PH12017501004A1 (en) | 2017-12-18 |
| US20180207231A1 (en) | 2018-07-26 |
| BR112017011530A2 (pt) | 2018-03-13 |
| WO2016090022A8 (en) | 2017-06-22 |
| EP3227313A1 (en) | 2017-10-11 |
| SG11201704427YA (en) | 2017-06-29 |
| EP3227313B1 (en) | 2022-02-09 |
| AU2015358504A8 (en) | 2017-07-13 |
| JP6730988B2 (ja) | 2020-07-29 |
| PT3227313T (pt) | 2022-04-12 |
| US11723951B2 (en) | 2023-08-15 |
| WO2016090022A9 (en) | 2016-08-25 |
| PL3227313T3 (pl) | 2022-05-09 |
| KR20170085132A (ko) | 2017-07-21 |
| CN107250154A (zh) | 2017-10-13 |
| IL252426A0 (en) | 2017-07-31 |
| MX2017007059A (es) | 2018-05-02 |
| ES2910017T3 (es) | 2022-05-11 |
| TW201632542A (zh) | 2016-09-16 |
| WO2016090022A1 (en) | 2016-06-09 |
| EA201791212A1 (ru) | 2018-01-31 |
| AU2015358504A1 (en) | 2017-06-29 |
| DK3227313T3 (da) | 2022-04-19 |
| US10722551B2 (en) | 2020-07-28 |
| JP2017538407A (ja) | 2017-12-28 |
| JP2020073610A (ja) | 2020-05-14 |
| US20210015895A1 (en) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102890A1 (es) | Polipéptidos que comprenden una secuencia de aminoácidos g3p de bacteriófago sin señal de glucosilación | |
| CL2018003697A1 (es) | Interferón porcino pegilado y métodos de uso del mismo. | |
| CL2017002731A1 (es) | Adenovirus oncolítico que codifica una proteína b7 | |
| PE20190335A1 (es) | Receptores de celulas t | |
| CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
| BR112018072915A2 (pt) | peptídeo cíclico isolado e composição farmacêutica | |
| BR112016025297A2 (pt) | adenovírus que compreende uma porção de ligação a albumina | |
| CY1122615T1 (el) | Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου | |
| CL2018001159A1 (es) | Vacuna para adenovirus aviar (divisional de solicitud n° 358-2016) | |
| PE20191152A1 (es) | Anticuerpos y polipeptidos dirigidos contra cd127 | |
| CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| PH12015502585A1 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity | |
| BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
| BR112018014288A2 (pt) | métodos e composições para o tratamento de doença neurológica | |
| MX2016002891A (es) | Virus recombinantes de la enfermedad de marek y usos de los mismos. | |
| CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
| AR109538A1 (es) | Vacuna contra la gripe porcina | |
| CY1124738T1 (el) | Συνθεσεiς εμβολιων που περιλαμβανουν τρυπτοφανη 2,3-διοξυγεναση ή θραυσματα αυτης | |
| AR101814A1 (es) | Partícula de tipo virus flavivirus | |
| BR112018015453A2 (pt) | vírus atenuado da bronquite infecciosa | |
| AR093569A1 (es) | Tensioactivos pulmonares reconstituidos | |
| CY1125014T1 (el) | Υποκατεστημενα παραγωγα ξανθινης | |
| AR087034A1 (es) | Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas | |
| AR084095A1 (es) | Peptidos tomm34 y vacunas que los incluyen | |
| CL2020003220A1 (es) | Nueva proteína con propiedades antiinflamatorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |